(Q38072312)

28 August 2017

1 reference

title

Rheumatoid arthritis in 2012: Progress in RA genetics, pathology and therapy (English)

1 reference

28 August 2017

0 references

0 references

Ronald van Vollenhoven

series ordinal

1

object named as

Ronald F van Vollenhoven

0 references

language of work or name

English

0 references

publication date

8 January 2013

1 reference

Nature Reviews Rheumatology

28 August 2017

published in

1 reference

28 August 2017

volume

9

1 reference

28 August 2017

issue

2

1 reference

28 August 2017

page(s)

70-72

1 reference

https://scigraph.springernature.com/pub.10.1038/nrrheum.2012.232

28 August 2017

exact match

0 references

cites work

Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.232

Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.232

Effect of body mass index on mortality and clinical status in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.232

Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.232

A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.232

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.232

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.232

Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.232

Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: a long-term followup from disease onset.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.232

Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.232

31 March 2020

Identifiers

DOI

10.1038/NRRHEUM.2012.232

1 reference

Dimensions Publication ID

28 August 2017

1013833294

0 references

1 reference